FirstOnSite Restoration grows presence in Alberta and Saskatchewan with acquisition of Spectrum Restoration

Acquisition represents continued growth and deepens FirstOnSite’s commercial capabilities in the Prairies

MISSISSAUGA, Ontario, Nov. 24, 2020 (GLOBE NEWSWIRE) — FirstOnSite Restoration, Canada’s leading independent disaster restoration services provider, has strengthened its presence in Alberta and Saskatchewan with the signing of an agreement to acquire Spectrum Restoration, a family run business since 2006.

Spectrum Restoration is a regional full-service commercial and residential restoration leader with experience managing commercial large loss projects, a focus on utilizing technology and an emphasis on customer service. Spectrum has approximately 40 employees across two locations: Lloydminster and Cold Lake, AB. It is headquartered in Lloydminster – a unique city that straddles the borders of Alberta and Saskatchewan and thus conveniently located to service commercial and residential customers in both provinces.

Spectrum Restoration has been operating for the past 14 years under the leadership of Greg and Travis Stieb. Travis Stieb, who has been instrumental in the growth and development of the commercial large loss business, will be taking on the role of Senior Project Manager, Complex Commercial Division. Rick Stephens, with an extensive background in operations management, will be assuming the role of Branch Manager for both the Lloydminster and Cold Lake locations.

“This acquisition represents an important expansion for FirstOnSite that closes a geographical service gap in the Prairies, allowing us to reach new customers and expand our coverage for our existing partners.” said Bill Moorman, SVP, Western Operations, FirstOnSite Restoration. “By adding Travis to our commercial loss team, we gain a very talented project manager with a reputation for doing what’s right for customers and employees. We see a strong alignment in values in many ways and believe he will be a great addition to FirstOnSite.”

“Spectrum Restoration complements FirstOnSite’s business very nicely and fits in with our strategic focus on growing our commercial capabilities across the country,” said Dave Demos, CEO. “Spectrum is well known for its residential restoration services and its exceptional abilities to manage large loss commercial projects. Combined with the strength that FirstOnSite’s corporate structure offers, we anticipate this acquisition will generate significant growth in the region.”

“FirstOnSite has been a trusted partner and we are thrilled at the opportunity to join forces with a large, sophisticated company that shares the same passion for large loss restoration,” said Travis Stieb, Spectrum Restoration. “With the systems and infrastructure of a large corporation, not only will FirstOnSite provide support and the ability to scale up when large loss disasters hit, it will provide our employees with room for advancement, giving them more potential in their career paths.”

The deal is scheduled to close on December 1, 2020. Terms of the transaction, including purchase price, were not disclosed.

About FirstOnSite Restoration

Founded in 2007 and based in Mississauga, ON, FirstOnSite Restoration Limited is one of the largest emergency restoration and reconstruction service providers in North America. FirstOnSite Restoration is a subsidiary of FirstService Corporation. In 2016, FirstOnSite joined forces with Interstate Restoration, a leading disaster restoration services provider for commercial enterprises in the U.S. With greater than 2,000 employees and more than 75 locations, FirstOnSite Restoration and Interstate assist property owners and businesses in recovering from fire, flood, natural and human-caused disasters.

For more information visit: www.firstonsite.ca or call 1.877.778. 6731, and follow @firstonsite on Twitter at www.twitter.com/firstonsite.

Press Contact:

Christine Alfred
MAVERICK
(416) 577-4052
[email protected]



Innovative Payment Solutions, Inc. Launches Joint Marketing Venture with Planet Hunny, Inc. to Expand its Reach to the U.S. Latino community

NORTHRIDGE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — (via InvestorWire) – Innovative Payment Solutions (“Innovative” or the “Company”) (OTCQB: IPSI), a U.S.-based fintech company building a 21st century digital payment solution, today announces the launch of a joint marketing venture with social marketing company Planet Hunny, Inc (“Planet Hunny”) to help expand the Company’s reach to the U.S.-based Latino community of 17 million people.

The joint marketing venture will leverage Planet Hunny’s influencers in order to reach specific Latin-American markets to expand Innovative’s access to Hispanic users and also will work toward the cross-pollination of all customers in Innovative’s network, introducing them to Planet Hunny.

Innovative brings to the joint marketing venture its extensive experience from the five years of its operations in Mexico, with over 2 million local users and a built-up fintech ecosystem in place that uses multiple devices in order to help meet the needs of both consumers and service providers.

Planet Hunny has established relationships with a variety of influencers and celebrities in sports, modeling and the pageantry world and is able to reach audiences of between 10 million and 20 million people in these niches, resulting in a scope of more than 35 million total users. Planet Hunny’s association with Being Latino, one of the nation’s leading U.S. Hispanic social media marketing companies, should also be particularly invaluable, and it is expected that its influencer and celebrity force will act as a traffic generator for the Innovative platform and ecosystem through a joint collaboration and marketing campaign.

“We see a tremendous opportunity for Innovative to reach new users, including millennials and Gen Z, by entering into this relationship,” stated William Corbett, president and CEO of Innovative. “Planet Hunny’s network and marketing expertise will provide us with additional exposure to Latino communities while approaching vertical markets. We believe it is a perfect tool to reach more users and offer our services to targeted underbanked and unbanked Latin-American users. Planet Hunny has built a solid team of seasoned professionals with a strong advisory board. We are extremely excited about this engagement.”

“Planet Hunny is a believer in execution,” added Jeff Vanderpol, president and founder of Planet Hunny. “Our companies have identified multiple points where our interests are mutually aligned, and we view this engagement as beneficial to our respective business models. Innovative will be our major fintech client, and we are looking forward to leveraging our expertise, merging our efforts and serving the unbanked/underbanked communities together.”

About
Planet
Hunny

Planet Hunny is a content platform that aggregates content from social influencers and affiliate partners to create a unique discovery experience for users. The company is also building a powerful database with new insights and trends daily, while creating a formidable customization “mirror” of user preferences based on the ultimate data analytics to offer products and services reflecting user desires. Planet Hunny is a proud Host Channel Partner of Being Latino – the No.2 most engaging branded content publisher in the U.S. on Facebook year-to-date. (http://www.Hunny.io/)

About Innovative Payment Solutions, Inc

Innovative Payment Solutions, Inc. (“Innovative”) strives to offer cutting-edge digital payment solutions for consumers and service providers. Innovative’s ecosystem will span multiple devices, such as self-service kiosks, mobile applications and POS terminals, offering alternative payment methods, including money remittance, to meet the needs of consumers and service providers. (https://www.innovatepaysolve.com)

SAFE HARBOR STATEMENT

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statement of historical fact contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate, “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should” or “will” or the negative of these terms or other comparable terminology and include statements regarding expanding the Company’s reach to the U.S.-based Latino community of 17 million people; Planet Hunny’s association with Being Latino being particularly invaluable; Being Latino’s influencer and celebrity force acting as a traffic generator for the Innovative platform and ecosystem; the opportunity for the Company to reach new users, including millennials and Gen Z, by entering into the relationship; and Planet Hunny being a perfect tool to reach more users and offer the Company’s services to targeted underbanked and unbanked Latin-American users. These forward-looking statements are based on expectations and assumptions as of the date of the press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, our ability to leverage Planet Hunny’s influencers to expand the Company’s reach to the U.S.-based Latino community of 17 million people; our ability to use Planet Hunny’s association with Being Latino to generate traffic for the Company’s platform and ecosystem; our ability to use Planet Hunny’s network and marketing expertise to reach new users, including millennials and Gen Z; the contribution of Planet Hunny to reaching more users and offer the Company’s services to targeted underbanked and unbanked Latin-American users; our ability to position the Company for future profitability; the duration and scope of the COVID-19 outbreak worldwide, including the impact to the economies in California and Mexico; and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended Dec. 31, 2019, and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events or otherwise, except as required by law.

For investor inquiries, please call (818) 864-4004 or email: [email protected].

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]



Kura Oncology to Host Virtual Investor Event on December 5, 2020

Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH

SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event to provide a review of the Company’s oral, potent and selective menin inhibitor, KO-539, following the oral presentation of preliminary clinical data at the 62nd American Society of Hematology (ASH) Annual Meeting. The event will feature members of the Kura management team along with two of the investigators from KOMET-001, an ongoing Phase 1/2A clinical trial of KO-539. The virtual event will take place at 2:00 p.m. ET / 11:00 a.m. PT on Saturday, December 5, 2020.

A live video webcast of the event will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available shortly after the conclusion of the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed or refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
[email protected]

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
[email protected]

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
[email protected]



Mandalay Resources Corporation Announces Recent Drilling Results For Aurora (Björkdal), Highlighting High-Grade Extensions to Both the East and at Depth

TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) — Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND, OTCQB: MNDJF) is pleased to provide an update on encouraging results from the Aurora extension and delineation drill programs at its Björkdal mine. These results highlight the open nature of the plunge extensions and an emerging new high-grade domain.


Aurora


Drilling


Highlights

Extensional drilling to the east and down plunge:

  • 4.
    8
    g/t
    gold
    over a true width of
    2
    .
    47
    m in MU20-007; and
  • 2.7
    g/t
    gold
    over a true width of
    2
    .
    82
    m in MU20-016

Definition drilling to the east:

  • 8.1
    g/t
    gold
    over a true width of
    2.99
    m in DOD2020-063; and
  • 3.0
    g/t gold
    over a true width of
    3.4
    5
    m in DOD2020-073

Surrounding veining highlights:

  • 14
    .5
    g/t gold over a true width of
    2.9
    2
    m in DOD2020-060; and
  • 38.7
    g/t gold over a true width of
    0.
    59
    m in DOD2020-074; and
  • 55.6
    g/t gold over a true width of 0.
    28
    m in MU20-018

Note: A full listing of significant drilling composites can be found in Tables 1 and 2 at the bottom of this document.

Dominic Duffy, President and Chief Executive Officer of Mandalay, commented, “We are pleased to report continued encouraging results from the Aurora extension program. These results come at a time when ore production from Aurora is ramping up and becoming the most significant ore source for Björkdal.”

Mr. Duffy continued, “With the exceptional grades seen at Aurora, its extension – both to the east and west – represents an important incremental step for Björkdal providing the foundation to bolster overall feed grade and extend mine life. We are also encouraged by some very high-grade intercepts of veins in close proximity to Aurora which will also be a focus of additional drilling going forward.”

Mr. Duffy continued, “With the current exploration focus turned to strategic development of other targets within Björkdal, we look forward to continuing the Aurora expansion program in early 2021.”

Mr. Duffy concluded, “Alongside this exploration release, a video has been prepared by Mr. Chris Davis, Vice President of Operational Geology and Exploration to further illustrate the detail in this press release, I would like to invite everyone to view the posted video here.”


Aurora Extensional Drilling

The Aurora Extensional Drilling has continued since Mandalay’s last Aurora update in June 2020. To the east MU20-016 returned an intercept of 2.82 m @ 2.7 g/t Au, indicating the plunge extent of Aurora is still open at depth. This was supported by MU20-013 with a reasonably well mineralized array of veining over 3.02 m at 1.6 g/t Au, typical of Aurora, intercepted approximately 60 m above. Higher in the system there has been a reinterpretation of Aurora veining due to new information mining and other drilling results. As a consequence MU20-007 was reinterpreted to include a high-grade composite of 2.47 m at 4.8 g/t Au that, combined with another previously reported intercept (MU20-018 at 7.21 m at 2.5 g/t Au) to the north, highlights a new enriched domain open to the east (see Figure 2).

Further drilling to the east within holes MU20-030 and MU20-032 did not intercept significant mineralization along the interpreted Aurora continuation however in both cases the footwall veining was enriched with 0.25 m at 23.5 g/t Au in MU20-030 and 0.96 m at 12.4 g/t in MU20-032 (see Figure 1). This could indicate a jump across structures of the gold endowment or an as yet unrecognised offset to the main Aurora structure. These results represent the furthest intercepts yet drilled to the east. Continuation of the extension campaign is expected in early 2021.


Surrounding Veining

As well as delineating and extending Aurora the drilling is providing grade information on the stacked set of veins that exist in both the footwall and hanging wall. As seen in MU20-30 and MU20-32, these veins are sometimes higher grade than Aurora and are an important addition to the production potential of the Björkdal mine. In the last Resource update for Björkdal, Aurora made up approximately 45% of metal in resource from veining above the marble contact with the remainder in the surrounding veining. Results from the surrounding veining within recent drilling can be found in Table 2 and illustrated within Figure 1.


Western


D


efinition


D


rilling

Due to the complicated nature of the veining and gold enrichment within and around Aurora, it is necessary to undertake targeted definition drilling to optimise ore extraction. From this drilling Mandalay has discovered that the Aurora system is also open to the west with encouraging intercepts following along the Frea Fault interaction such as 3.17 m at 3.0 g/t Au in DOD2020-075 and 4.66 m at 2.1 g/t Au in DOD2020-072. In this area approximately 15 additional continuous veins exist alongside Aurora with highlights of 0.59 m at 38.7 g/t Au in DOD2020-074 and 0.37 m at 31.7 g/t in DOD2020-075. As with the extension to the east, a drilling program will focus on extension along this trend in early 2021.

Figure 1. North-South Cross Section at illustrating the location and orientation of the new intercepts surrounding Aurora between 1550 E and 1650 E is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/65c1259e-a6a4-4c35-afc4-a58fe4aa3ed8. Veining and interpreted lithology is displayed at 1600 E. The DOD series of holes are drilled further to the west and are not shown on this section.

Figure 2. Longitudinal section of Aurora illustrating the location of recent extension and definition drilling results is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/98b65977-3ee7-4386-a792-d98da87f9249.


Drilling and Assaying

At Björkdal, all diamond drill core was logged and sampled by Björkdal geologists. Exploration drill hole samples (prefix MU) were sent to CRS Laboratories Oy (“CRS”) in Kempele, Finland for sample preparation and assaying. Development optimization drill hole samples (prefix DOD) were prepared and assayed at the onsite laboratory ran by Minlab AB, a subsidiary of CRS (see Technical Report dated March 30, 2020 entitled “Technical Report on the Björkdal Gold Mine, Sweden”, available on SEDAR (www.sedar.com), which contains a complete description of drilling, sampling, and assaying procedures).

Assaying was conducted utilizing the Pal1000 cyanide leaching processes. Mandalay’s rigorous QA/QC program included the use of standard reference samples, blanks, duplicates, repeats, and internal laboratory quality assurance procedures.


Qualified Person:

Chris Davis, Vice President of Operational Geology and Exploration at Mandalay Resources, is a Charted Professional of the Australian Institute of Mining and Metallurgy (MAusIMM CP(Geo)), and a Qualified Person as defined by NI 43-101. He has reviewed and approved the technical and scientific information provided in this release.


For Further Information

Dominic Duffy
President and Chief Executive Officer

Edison Nguyen
Manager, Analytics and Investor Relations

Contact:
647.260.1566


About Mandalay Resources Corporation

Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. The Company is focused on growing production at its gold and antimony operation in Australia, and gold production from its operation in Sweden to generate near term cash flow.


Forward-Looking Statements:

This news release contains “forward-looking statements” within the meaning of applicable securities
laws,
including
statements
regarding
the
exploration
and
development
potential
of the
Aurora
Zone
(Björkdal).
Readers
are
cautioned
not
to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things,
changes
in
commodity
prices
and
general
market
and
economic
conditions.
The
factors identified
above
are
not
intended
to
represent
a
complete
list
of
the
factors
that
could
affect Mandalay.
A
description
of
additional
risks
that
could
result
in
actual
results
and
developments differing
from
those
contemplated
by
forward-looking
statements
in
this
news
release
can
be found
under
the
heading
“Risk
Factors”
in
Mandalay’s
annual
information
form
dated
March 30, 2020, a copy of which is available under Mandalay’s profile at

www.sedar.com.

In addition, there can be no assurance that any inferred resources that are discovered as a result of additional
drilling
will
ever
be
upgraded
to
proven
or
probable
reserves.
Although
Mandalay
has attempted to identify important factors that could cause actual actions, events or results to differ
materially
from
those
described
in
forward-looking
statements,
there
may
be
other
factors that
cause
actions,
events
or
results
not
to
be
as
anticipated,
estimated
or
intended.
There
can be no assurance that forward-looking statements will prove to be accurate, as actual results and
future
events
could
differ
materially
from
those
anticipated
in
such
statements.
Accordingly, readers
should
not
place
undue
reliance
on
forward-looking
statements.

Table 1
. New Drilling Composites on Aurora

Drill Hole ID From (m) To (m) Drill Width (m) True Width (m) Au Grade (g/t) Au (g/t) over min. 3m mining width Target
DOD2020-058 77 80.65 3.65 2.81 0.2 0.1 Western Definition
DOD2020-059 87.9 93.52 5.62 3.78 0.4 0.4 Western Definition
DOD2020-060 79.65 85 5.35 4.25 0.8 0.8 Western Definition
DOD2020-061 66.6 70.2 3.60 3.33 0.9 0.9 Western Definition
DOD2020-063 94.25 98.4 4.15 2.99 8.1 8.1 Western Definition
DOD2020-072 148.5 153.2 4.70 4.66 2.1 2.1 Western Definition
DOD2020-073 142.25 145.7 3.45 3.45 3.0 3.0 Western Definition
DOD2020-074 145.7 149.5 3.80 3.77 0.2 0.2 Western Definition
DOD2020-075 139.05 142.25 3.80 3.17 3.0 3.0 Western Definition
DOD2020-076 145.45 148.3 3.80 2.67 0.2 0.2 Western Definition
DOD2020-097 121 126.6 5.55 3.50 0.7 0.7 Western Definition
DOD2020-099 107.2 113.8 6.55 4.63 2.0 2.0 Western Definition
MU20-007 323.45 326.2 2.75 2.47 4.8 3.9 Eastern Extension
MU20-013 216.1 219.55 3.45 3.02 1.6 1.6 Eastern Extension
MU20-016 271.6 276.6 5.00 2.82 2.7 2.5 Eastern Extension
MU20-017 188.3 197.75 9.45 7.30 0.6 0.6 Eastern Extension
MU20-030 132 135.4 3.40 2.36 0.6 0.5 Eastern Extension
MU20-031 161.95 163.85 1.90 1.17 0.4 0.1 Eastern Extension
MU20-032 208.25 211.15 2.90 1.89 1.6 1.0 Eastern Extension

Notes

  1. Where True widths are greater than 3 m, grades are not diluted and are presented as the grade over the composite true width.

Table 2
. New Drilling Composites Surrounding Aurora

Drill Hole ID From (m) To (m) Drilled Width (m) True Width (m) Au Grade (g/t) Au (g/t) over min. 3m mining width Description
DOD2020-058 71.00 72.80 1.80 1.60 2.9 1.6 Foot Wall Veining
DOD2020-060 73.60 77.80 4.20 2.92 14.5 14.1 Foot Wall Veining
DOD2020-060 115.00 115.35 0.35 0.25 9.5 0.8 Hanging Wall Veining
DOD2020-061 52.55 60.10 7.55 6.51 2.6 2.6 Foot Wall Veining
DOD2020-061 97.30 97.70 0.40 0.31 8.9 0.9 Hanging Wall Veining
DOD2020-063 133.80 134.10 0.30 0.19 57.4 3.6 Hanging Wall Veining
DOD2020-072 83.80 84.75 0.95 0.92 9.7 3.0 Foot Wall Veining
DOD2020-072 116.10 116.50 0.40 0.31 5.9 0.6 Foot Wall Veining
DOD2020-072 157.75 158.75 1.00 0.78 4.8 1.3 Hanging Wall Veining
DOD2020-072 187.55 188.10 0.55 0.50 7.6 1.3 Hanging Wall Veining
DOD2020-072 191.50 192.00 0.50 0.49 3.8 0.6 Hanging Wall Veining
DOD2020-073 48.05 48.65 0.60 0.59 5.8 1.1 Foot Wall Veining
DOD2020-073 64.50 64.85 0.35 0.31 6.3 0.6 Foot Wall Veining
DOD2020-073 153.15 153.60 0.45 0.44 3.8 0.6 Hanging Wall Veining
DOD2020-073 178.05 179.65 1.60 1.59 4.9 2.6 Hanging Wall Veining
DOD2020-073 185.70 186.00 0.30 0.21 24.3 1.7 Hanging Wall Veining
DOD2020-074 32.70 33.30 0.60 0.59 38.7 7.6 Foot Wall Veining
DOD2020-074 131.95 132.35 0.40 0.39 16.0 2.1 Foot Wall Veining
DOD2020-074 153.70 156.10 2.40 2.15 2.0 1.4 Hanging Wall Veining
DOD2020-074 165.90 167.75 1.85 1.80 3.5 2.1 Hanging Wall Veining
DOD2020-074 185.60 185.95 0.35 0.34 6.1 0.7 Hanging Wall Veining
DOD2020-075 31.60 32.05 0.45 0.42 5.6 0.8 Foot Wall Veining
DOD2020-075 52.75 53.10 0.35 0.34 7.7 0.9 Foot Wall Veining
DOD2020-075 77.00 77.35 0.35 0.33 5.1 0.6 Foot Wall Veining
DOD2020-075 108.75 109.10 0.35 0.31 9.3 1.0 Foot Wall Veining
DOD2020-075 123.20 124.60 1.40 1.29 3.2 1.4 Foot Wall Veining
DOD2020-075 170.15 170.65 0.50 0.34 10.3 1.2 Hanging Wall Veining
DOD2020-075 180.80 181.20 0.40 0.37 31.7 3.9 Hanging Wall Veining
DOD2020-075 190.25 190.60 0.35 0.31 13.3 1.4 Hanging Wall Veining
DOD2020-076 29.88 30.25 0.37 0.27 6.1 0.5 Foot Wall Veining
DOD2020-076 51.40 52.83 1.43 1.36 1.8 0.8 Foot Wall Veining
DOD2020-076 103.00 103.35 0.35 0.29 7.4 0.7 Foot Wall Veining
DOD2020-076 117.30 117.65 0.35 0.27 12.4 1.1 Foot Wall Veining
DOD2020-076 126.15 126.50 0.35 0.32 6.5 0.7 Foot Wall Veining
DOD2020-076 157.20 157.70 0.50 0.31 5.6 0.6 Hanging Wall Veining
DOD2020-076 163.00 164.45 1.45 1.38 3.3 1.5 Hanging Wall Veining
DOD2020-076 183.35 183.70 0.35 0.31 15.0 1.6 Hanging Wall Veining
DOD2020-076 196.30 199.30 3.00 2.69 2.1 1.9 Hanging Wall Veining
DOD2020-076 201.65 202.00 0.35 0.31 5.1 0.5 Hanging Wall Veining
DOD2020-097 111.25 112.25 1.00 0.78 3.5 0.9 Foot Wall Veining
DOD2020-097 166.15 166.80 0.65 0.37 7.9 1.0 Hanging Wall Veining
DOD2020-099 112.90 113.75 0.85 0.70 4.0 0.9 Hanging Wall Veining
DOD2020-099 139.55 139.95 0.40 0.29 11.2 1.1 Hanging Wall Veining
MU20-007 229.30 230.00 0.70 0.61 2.7 0.6 Foot Wall Veining
MU20-008A 320.05 321.95 1.90 1.90 1.4 0.9 Foot Wall Veining
MU20-009A 327.05 329.00 1.95 1.07 14.5 5.2 Foot Wall Veining
MU20-009A 338.40 338.85 0.45 0.27 5.9 0.5 Foot Wall Veining
MU20-011 177.60 178.50 0.90 0.78 2.5 0.6 Foot Wall Veining
MU20-011 271.60 273.00 1.40 0.30 7.2 0.7 Foot Wall Veining
MU20-011 278.75 279.25 0.50 0.23 32.5 2.5 Foot Wall Veining
MU20-011 337.45 338.65 1.20 0.29 13.9 1.3 Hanging Wall Veining
MU20-011 362.20 362.75 0.55 0.26 6.2 0.5 Hanging Wall Veining
MU20-011 371.60 372.00 0.40 0.31 5.1 0.5 Hanging Wall Veining
MU20-012 119.70 120.00 0.30 0.29 6.5 0.6 Foot Wall Veining
MU20-014 191.30 192.15 0.85 0.78 6.2 1.6 Hanging Wall Veining
MU20-015 153.75 154.70 0.95 0.79 2.9 0.8 Hanging Wall Veining
MU20-016 27.90 28.60 0.70 0.70 3.4 0.8 Foot Wall Veining
MU20-016 224.40 224.75 0.35 0.20 12.5 0.8 Foot Wall Veining
MU20-017 167.65 168.15 0.50 0.34 5.6 0.6 Foot Wall Veining
MU20-018 114.20 114.65 0.45 0.44 3.7 0.5 Foot Wall Veining
MU20-018 194.40 195.25 0.85 0.78 4.5 1.2 Hanging Wall Veining
MU20-030 96.20 96.55 0.35 0.25 23.5 2.0 Foot Wall Veining
MU20-032 155.70 156.85 1.15 0.96 12.4 4.0 Foot Wall Veining

Notes

  1. Where True widths are greater than 3 m, grades are not diluted and are presented as the grade over the composite true width.
  2. Composites that are below 0.5 g/t Au when diluted to 3 m are not reported in this table.



iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis

– Methods for Production in iBio’s FastPharming® System Foundational to Antifibrotic Development Program –

BRYAN, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,844,392, entitled “Materials and Methods for Producing Endostatin Fusion Polypeptides in Plant Cells,” which, amongst other claims, covers a novel expression cassette that enhances the yield of endostatin fragments and variants using iBio’s FastPharming® System.

The claims in the patent are foundational to iBio’s work on its antifibrotic therapies given that the technologies enhance the expression and quality of endostatin-derived E4 antifibrotic peptides fused to human IgG1 when produced in plants. The Company is developing such a molecule as “IBIO-100” for the treatment of fibrotic disorders, including systemic scleroderma and idiopathic pulmonary fibrosis. The ‘392 Patent contains 19 claims and expires in June 2036.

“This patent, and the technologies it covers, advances our work on therapeutic candidates for treating fibrotic disorders by increasing the number of antifibrotic peptide variants that we may select for clinical development,” said Tom Isett, Chairman & CEO of iBio. “iBio can also apply certain claims to other IgG-based molecules manufactured using our FastPharming System, thereby creating the opportunity to secure additional intellectual property based upon composition of matter.”

iBio plans to conduct IND-enabling studies on IBIO-100 in 2021.

About
iBio
, Inc.

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBio’s Glycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products, which include IBIO-100 for the treatment of fibrotic diseases, and vaccines for infectious diseases. For more information, visit www.ibioinc.com.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding developing “IBIO-100” for the treatment of fibrotic disorders, including systemic scleroderma and idiopathic pulmonary fibrosis, securing additional intellectual property based upon composition of matter by applying certain claims to other IgG-based molecules manufactured using our FastPharming System and plans to conduct IND-enabling studies on IBIO-100 in 2021. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to conduct additional investigational new drug-enabling studies in the first half of 2021 as planned, the Company’s ability to obtain regulatory approvals for commercialization of its product candidates, including its COVID-19 vaccines, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, the Company’s ability to enroll patients and complete clinical trials on time and achieve desired results and benefits as expected, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its intellectual property portfolio, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other risk factors discussed in the Company’s most recent Annual Report on Form 10-K and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contact
s
:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
[email protected]



Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19

– Data Expected
Second Quarter
2021 –


The INSPIRE Trial Is
Designed
t
o
Assess
t
he Ability
o
f CAP-1002
t
o
Modulate
t
he Cytokine Storm Associated With Severe COVID-19

LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today that the first two patients have been dosed in its Phase 2 study evaluating intravenous infusion of CAP-1002 – its lead clinical asset – using its allogeneic cardiosphere-derived cells (CDC) technology as a treatment option for patients with COVID-19. The study is now enrolling patients who have been diagnosed with SARS-CoV-2 and require supplemental oxygen. The study is being conducted at multiple sites in the United States and will enroll up to 60 patients.

“This trial represents a significant milestone for Capricor, as we expand the scope of our CAP-1002 program to treat patients with severe COVID-19. As hospitalizations continue to increase, we have a therapeutic under investigation for patients at a high-risk for significant morbidity or even death,” said Linda Marbán, Ph.D., President and Chief Executive Officer of Capricor. “It is important to remember that many patients are suffering from long term cardiac consequences from COVID-19. As CAP-1002 directly targets cardiac dysfunction, CAP-1002 potentially may also be an important tool in the treatment of the cardiac complications of COVID-19.”

Within the framework of SARS-CoV-2 pathogenesis, multiple pathways known to be CAP-1002 sensitive may serve as therapeutic targets. These targets include pro-inflammatory pathways (TNF-α, interferon γ, IL-1, and IL-6) and anti-inflammatory pathways (regulatory T cells and IL-10) that have been explored with CAP-1002 in preclinical models of myocardial ischemia, myocarditis, heart failure, muscular dystrophy and pulmonary hypertension. Given that CAP-1002 polarizes macrophages to an anti-inflammatory (healing) immunomodulatory phenotype, CAP-1002 may subsequently attenuate cytokine storm.

The INSPIRE trial (NCT04623671) is a Phase 2, randomized, double-blind, placebo-controlled study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and are in severe or critical condition as indicated by life-support measures. The primary objectives of the study are to determine the safety and effectiveness of intravenously infused CAP-1002 for improving clinical outcomes in severe to critical patients with COVID-19. Eligible subjects will be randomized to either the CAP-1002 or placebo group (1:1 ratio) and undergo baseline safety and efficacy assessments approximately one to three days prior to the administration of investigational product (IP).

“We remain committed to developing therapeutic options for patients diagnosed with severe COVID-19 in parallel to the exciting developments recently reported on our exosome platform technology. We look forward to announcing more updates on these programs as they become available,” concluded Dr. Marbán.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform. For more information, visit www.capricor.com and follow the Company on FacebookInstagram and Twitter.

About CAP-1002

CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has been shown in pre-clinical and clinical studies to exert potent immunomodulatory activity. It is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. CDCs have been the subject of over 100 peer-reviewed scientific publications and administered to approximately 200 human subjects across several clinical trials.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on November 13, 2020. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.

For more information, please contact:

Media Contact:

Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
[email protected] / [email protected]
212.896.1241 / 212.896.1204

Investor Contact:

Joyce Allaire
LifeSci Advisors, LLC
[email protected]
617.435.6602

Company Contact:

AJ Bergmann, Chief Financial Officer
[email protected]
310.358.3200



Thryv, Inc. to Participate in The Wells Fargo TMT Summit 2020

Dallas, Nov. 24, 2020 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ:THRY), the provider of Thryv® software, the end-to-end client experience platform for small businesses, today announced that CEO and President Joe Walsh will participate in a question and answer session at the Wells Fargo TMT Summit on December 1 at 4:40 p.m. ET.

A live webcast will be available on Thryv’s Investor Relations page at investor.thryv.com. An archived replay will be made available for a limited time at the same location following the event.

About Thryv Holdings, Inc.

The company owns the easy-to-use Thryv® end-to-end customer experience software built for small business that helps over 40,000 SaaS clients with the daily demands of running a business. With Thryv, they can get the job, manage the job and get credit. Thryv’s award-winning platform provides modernized business functions, allowing small-to-medium-sized businesses (SMB) to reach more customers, stay organized, get paid faster and generate reviews. These include building a digital customer database, automated marketing through email and text, updating business listings across the internet, scheduling online appointments, sending notifications and reminders, managing ratings and reviews, generating estimates and invoices and processing payments.

Thryv supports franchise operators and multi-location business owners with Hub by Thryv™, a software console that enables businesses managers to oversee their operations using the Thryv software.

Thryv also connects local businesses to consumer services through our search, display and social media management products, our print directories featuring The Real Yellow Pages® tagline, and our local search portals, which operate under the DexKnows.com®, Superpages.com® and Yellowpages.com URLs and reach some 35 million monthly visitors. For more information about the company, visit thryv.com.

Thryv delivers business services to more than 360,000 SMBs across America that enable them to compete and win in today’s economy.       

Learn more about Thryv on LinkedIn and Medium.

 

Media Contact:

Paige Blankenship

Thryv, Inc.

972.453.3012

[email protected]

 

Investor Contact:

Cameron Lessard 


Thryv, Inc.
    

214.773.7022 

[email protected]   

 

KJ Christopher

Thryv, Inc.

972.453.7068

[email protected]

 

###



Paige Blankenship
Thryv, Inc.
972.453.3012
[email protected]

CGE Energy Granted Sixth Patent for Innovative Wind Turbine

BRIGHTON, Mich, Nov. 24, 2020 (GLOBE NEWSWIRE) — CGE Energy, Inc. (OTCPink: CGEI) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,808,677 to the Company, entitled, “Fluid driven vertical axis turbine.” This patent relates to a fluid driven vertical axis turbine and its remote-controlled blades that fold up and lay flat against the rotor in dangerous, high-wind situations. The patent also covers the manner in which the turbine’s segmented blade joints hydraulically lock together to make a strong, rigid blade, both in the open and closed position.

“The issuance of this sixth patent enhances the strength of our intellectual property protection around our vertical axis wind turbine,” said Bryan Zaplitny, President and CEO of CGE Energy. “This patent further supports our ongoing R&D efforts in bringing unique off-grid power solutions to markets where power availability is an issue.”

To date, CGE Energy has received five U.S. patents as well as one European patent for the technology. These independent patents cover many aspects of the technology, including having a fluid driven turbine that generates power from wind blowing from any direction, its generator and primary components located in the base of the turbine, as well as the turbine’s easy delivery transport method.

In recent months, CGE Energy has expanded its management team that oversees the technology division of CGE Energy and its subsidiaries, as well as expanded its strategic partners to bring this technology to market.

About CGE Energy, Inc.


CGE Energy, Inc.

, and its wholly-owned subsidiary Clean Green Energy, Inc., is a developer of long-term energy projects and self-powered infrastructure which solve the unique energy challenges of their commercial, municipal and nonprofit customers. The Company provides both services and products that enable its customers to reduce their energy consumption; lower their upfront, operating and maintenance costs; and realize environmental benefits.

To learn more visit http://www.cgeenergy.com.

Press Release Contacts

CGE Energy, Inc.
Paul Schneider, VP Marketing
248-446-1344
[email protected]

Forward-Looking Statements

This release may contain “forward-looking statements” that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. All forward-looking statements included in this release are based on information available to us on the date hereof and speak only as of the date hereof. We undertake no obligation to update or revise publicly any forward-looking statements. Actual results may differ materially from those projected in the forward-looking statements.



ADM Endeavors, Inc. (ADMQ) Announces Shareholder Rewards Program

Fort Worth, TX, Nov. 24, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — ADM Endeavors, Inc. (OTCQB: ADMQ) is pleased to announce that it is rewarding its shareholders because of their strong commitment to the Company.  ADMQ is offering a 25 percent discount to shareholders of record each quarter for products on its website, www.JustRightProducts.com, where shareholders will find tens of thousands of unique products ranging business cards to coffee cups, from incredible wearables to health and fitness products.

The discount will be applied to a single order each quarter to shareholders of record.  Information about the program, including restrictions, is available at:  https://admendeavors.com/reward-program/.

ABOUT ADMQ: Since 2010, our wholly owned subsidiary, Just Right Products, Inc., has operated a diverse vertical integrated business in the Dallas/Fort Worth area, which consists of a retail sales division, screen print production, embroidery production, digital production, import wholesale sourcing, and uniforms. The Retail Sales Division focuses on any product with a logo. It sells a very wide range of products from business cards to coffee cups. Our motto is “We Sell Anything With A Logo!” Just Right Products’ salespeople excel because they are selling the items people like to buy. The Screen Printing Department utilizes its five screen printing machines to print garments and can produce more than 8,000 units per day. The Embroidery equipment has 51 heads of embroidery capacity. The Digital Department and all the other departments have significant growth potential. The Import Department sources products for retail and wholesale customers. ADM Endeavors has employees fluent in Chinese, Spanish and Arabic thereby affording significant opportunities to interact directly with multiple product sources internationally. The Uniform Division sells uniforms to businesses and schools, with the advantage of in-house production and international sourcing.

Forward Looking Statement:

This press release contains certain “forward-looking statements,” as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. The economic, competitive, governmental, technological and other factors identified in the Company’s previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: ADM Endeavors, Inc.

Paul Knopick

[email protected]

940.262.3584



Telesat to Become Public Company through Agreement with Loral Space & Communications and PSP Investments

Telesat to remain Canadian controlled, will become a publicly listed company on Nasdaq, and is considering listing on a Canadian stock exchange.

OTTAWA, Nov. 24, 2020 (GLOBE NEWSWIRE) — Telesat Canada announced today that it has entered into an agreement with Loral Space & Communications Inc. (NASDAQ: LORL) (Loral) and Public Sector Pension Investment Board (PSP Investments) pursuant to which Telesat Canada and Loral will become subsidiaries of Telesat Corporation (Telesat), a new publicly traded Canadian incorporated and controlled company.  The shares of Telesat will be listed on the Nasdaq Global Select Market at the closing of the transaction, the market on which Loral is currently listed, and Telesat is also considering a listing on a Canadian stock exchange in connection with the closing of the transaction in 2021. Telesat Corporation will be headquartered in Ottawa and led by Telesat Canada’s Chief Executive Officer Daniel S. Goldberg. Telesat’s voting and governance provisions will ensure that the company is and remains Canadian-controlled.

This transaction allows public market investors, including Loral’s stockholders, to own Telesat directly, and, moreover, provides Telesat access to the public equity markets to support its compelling growth initiatives, including its revolutionary, highly advanced low Earth orbit (LEO) satellite constellation. Telesat’s state-of-the-art LEO network will enable affordable, reliable, high-speed broadband connectivity everywhere on Earth, positioning Telesat to be a leader in this high growth industry.

“Today’s announcement rationalizes our corporate structure and is another important step in our efforts to execute our exciting growth strategy, deliver the most competitive and innovative services to our customers, and create value for our shareholders and other key stakeholders,” said Dan Goldberg, Telesat’s President and CEO. “Following the closing of the transaction, Telesat will have access to the public equity markets, providing increased flexibility and optionality to support our promising investment opportunities, including Telesat LEO, which will bridge the digital divide both at home in Canada and around the world, and give our customers the competitive advantage they need to be successful. We look forward to engaging with our expanded shareholder base as we implement our growth plans with a focus on generating strong equity returns.”

The transaction is expected to close in the second or third quarter of 2021, subject to the receipt of required regulatory approvals, the approval of Loral’s stockholders (including a majority of Loral’s stockholders not affiliated with MHR Fund Management, PSP Investments or other transaction participants) and other customary conditions.

Additional information with respect to the transaction will be available in filings made with the U.S. Securities and Exchange Commission by Telesat Canada and Loral.  Loral stockholders can obtain that information at www.sec.gov.

In connection with the transaction, Wachtell, Lipton, Rosen & Katz and Stikeman Elliott LLP acted as legal counsel to Telesat, and Goldman Sachs & Co. LLC and BMO Capital Markets acted as financial advisors to Telesat.

About Telesat

Backed by a legacy of engineering excellence, reliability and industry-leading customer service, Telesat has grown to be one of the largest and most successful global satellite operators. Telesat works collaboratively with its customers to deliver critical connectivity solutions that tackle the world’s most complex communications challenges, providing powerful advantages that improve their operations and drive growth. Telesat LEO, our Low Earth Orbit network, will revolutionize global broadband connectivity by delivering a combination of high capacity, security, resiliency and affordability with ultra-low latency and fiber-like speeds.

Privately held and headquartered in Ottawa, Canada with offices and facilities around the world, Telesat’s principal shareholders are Canada’s Public Sector Pension Investment Board and Loral Space & Communications Inc. (NASDAQ: LORL). For more information, visit https://www.telesat.com.

Media contact:                              

KWT Global for Telesat
[email protected]

Investor Relations:

Michael Bolitho
[email protected]

Cautionary Statement Regarding Forward-Looking Information

This new release contains statements that are not based on historical fact and are “forward-looking statements’’ within the meaning of the Private Securities Litigation Reform Act of 1995.  When used herein, statements which are not historical in nature, or which contain the words “will,” “expected,” “plans,” “considering,” or similar expressions, are forward-looking statements.  Actual results may differ materially from the expectations expressed or implied in the forward-looking statements as a result of known and unknown risks and uncertainties.

These forward-looking statements are based on Telesat’s current expectations and are subject to a number of risks, uncertainties and assumptions.  These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond Telesat’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.  Known risks and uncertainties include but are not limited to: risks associated with operating satellites and providing satellite services, including satellite construction or launch delays, launch failures, in-orbit failures or impaired satellite performance; the impact of COVID-19 on Telesat’s business and the economic environment; the ability to deploy successfully an advanced global Low Earth Orbit (“LEO”) satellite constellation, and the timing of any such deployment; the availability of government and/or other funding for the LEO satellite constellation; the receipt of proceeds in relation to the re-allocation of C-band spectrum; volatility in exchange rates; the ability to expand Telesat’s existing satellite utilization; risks associated with domestic and foreign government regulation; the ability to obtain regulatory approvals and Loral’s ability to obtain the stockholder approval required to consummate the transaction and the timing of such approvals and the closing of the transaction, including the risk that the conditions to the transaction are not satisfied on a timely basis or at all; the ability to complete the transaction on the expected terms and timing or at all; the outcome of any legal proceedings that may be instituted against Telesat, the other parties and others related to the transaction; unanticipated difficulties or expenditures relating to the transaction; the risk that expected benefits and growth prospects of the transaction may not be achieved in a timely manner or at all; the risk that disruption from the transaction may adversely affect Telesat’s business and its relationships with customers, suppliers or employees; and risks relating to the value of the shares of Telesat Corporation and limited partnership units of Telesat Partnership to be issued in connection with the transaction.  The foregoing list of important factors is not exhaustive.

Telesat believes these forward-looking statements are reasonable; however, you should not place undue reliance on any forward-looking statements, which are based on current expectations.  Furthermore, forward-looking statements speak only as of the date they are made.  Additional risks are detailed in Telesat’s Annual Report on Form 20-F for the fiscal year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 27, 2020, including, without limitation, those described under “Risk factors,” as updated by any Current Reports on Form 6-K and future filings with the SEC.  Except as may be required by applicable law, Telesat does not undertake any obligation to update or revise these forward-looking statements to reflect future events or circumstances.

Important Additional Information and Where to Find It

In connection with the transaction, Telesat Corporation and Telesat Partnership will file with the SEC a registration statement on Form F-4 that will contain a prospectus relating to the issuance of the shares of Telesat Corporation and limited partnership units of Telesat Partnership in connection with the transaction.  The registration statement will also include a proxy statement of Loral which will be sent to the stockholders of Loral in connection with the transaction.  Telesat Corporation and Telesat Partnership will also file a Canadian prospectus with the requisite Canadian securities authorities in connection with the transaction.  INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM F-4 AND THE RELATED PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT TELESAT, TELESAT CORPORATION, TELESAT PARTNERSHIP, LORAL AND THE PROPOSED TRANSACTION. 

Investors and security holders may obtain copies of these documents when they become available free of charge through the website maintained by the SEC at www.sec.gov and, for those documents filed with Canadian securities regulations, at the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com, or from Telesat at its website, https://www.telesat.com/investor-relations/ or from Loral at its website, www.loral.com, under the heading Investors.  Documents filed with the SEC by Telesat will be available free of charge by accessing Telesat’s website at www.telesat.com, under the heading Investors, or, alternatively, by directing a request by telephone or mail to Telesat at Investor Relations, 160 Elgin Street, Suite 2100, Ottawa, Ontario, Canada K2P 2P7, and documents filed with the SEC by Loral will be available free of charge by accessing Loral’s website at www.loral.com under the heading Investors or, alternatively, by directing a request by telephone or mail to Loral at Investor Relations, Loral Space & Communications Inc., 600 Fifth Avenue, New York, New York 10020.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Participants in the Solicitation

Telesat and Loral and certain of their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Loral in respect of the proposed transaction under the rules of the SEC.  Information about Loral’s directors and executive officers is available in Loral’s Annual Report on Form 10-K, as filed with the SEC on March 12, 2020, as amended on March 26, 2020 and certain of its Current Reports on Form 8-K.  Information about Telesat’s directors and executive officers is available in Telesat’s Annual Report on Form 20-F, filed with the SEC on February 27, 2020.  Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the transaction when they become available.  Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions.  You may obtain free copies of these documents from Loral or Telesat using the sources indicated above.